Loading clinical trials...

Effect on Wound Healing of Vigamox Versus Cravit | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Effect on Wound Healing of Vigamox Versus Cravit

Prospective, Randomized Study Comparing Effect on Wound Healing of Vigamox (Moxifloxacin 0.5% Ophthalmic Solution) and Cravit (Levofloxacin 0.5% Ophthalmic Solution) Administered Post-Surgically in Patients Undergoing Cataract Extraction

NCT00840580•Alcon Research

View on ClinicalTrials.gov

Summary

The purpose of this study was to compare the effects of Vigamox and Cravit on corneal wound healing after cataract surgery.

Eligibility

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients of any race and either sex, and over the age of 18, who are scheduled for removal of a cataract and implantation of a posterior chamber intraocular lens using clear corneal incisions or near-clear corneal incisions.
•Other than cataracts, have normal healthy eyes as determined by the ophthalmic examination and case history.
•Subconjunctival injections right after cataract surgery are allowed.

Exclusion Criteria

•Any cataract wound that is stitched or any gross abrasion of the epithelium after removal of a cataract and implantation of a posterior chamber intraocular lens.
•Fluorescein staining of the cornea at baseline.
•History or evidence of ocular or systemic disease, which would preclude participation in this study. Examples could include autoimmune disease affecting the cornea as well as any corneal dystrophies.
•History of ocular inflammatory disease, ocular herpes infection, iritis, uveitis, or Sjögren's syndrome.
•Known or suspected allergy or hypersensitivity to levofloxacin or any related medicines, such as cinoxacin (Cinobac), ciprofloxacin (Cipro or Ciloxan), norfloxacin (Chibroxin or Noroxin), ofloxacin (Floxin), or nalidixic acid (NegGram), preservatives, dyes, or any components of the study medication.
•Treatment for an ocular infection within 30 days prior to study entry.
•Use of topical or systemic steroids within 7 days prior to study entry.
•Use of topical anti inflammatory drugs within 7 days prior to study entry.
•Pregnancy, nursing/lactation, or inadequate birth control methods. Oral contraceptives are allowed.
•Patients with uncontrolled diabetes and/or diabetic retinopathy.
+1 more criteria

Locations (1)

Seoul, South Korea

Key Dates

Start Date

January 1, 2009

Primary Completion Date

September 1, 2009

Last Updated

July 23, 2012

Enrollment

ACTUAL participants

Conditions

Cataract Extraction

Interventions

Moxifloxacin 0.5% ophthalmic solution (Vigamox)

DRUG

Levofloxacin 0.5% ophthalmic solution (Cravit)

DRUG

PRO-232 in Patients Subjected to Cataract Surgery

NCT07305987

Cataract Extraction

View study

ENROLLING_BY_INVITATIONNA

Effectiveness of a Large Language Model-Based Educational Tool on Intraocular Lens Options

NCT07317661

Eye DisordersCataract Extraction+4 more

View study

COMPLETED

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 23, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effect on Wound Healing of Vigamox Versus Cravit

Inclusion Criteria

Exclusion Criteria

PRO-232 in Patients Subjected to Cataract Surgery

Effectiveness of a Large Language Model-Based Educational Tool on Intraocular Lens Options

Cerebral Oxymeter and End Tidal Carbondioxide Values Under Surgical Drapes With and Without Past COVID-19 Infection

Clinical Study to Evaluate the Efficacy and Tolerability of an Anti-inflammatory/Antibiotic Treatment Following Ocular Cataract Extraction

Epiretinal Macular Membrane and Cataract Extraction